Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01375127 · ClinicalTrials.gov registry record
Collection of Follow-up Data From CP-690,550-treated Kidney Transplant Recipients
A clinical trial of Kidney Transplantation, sponsored by Pfizer.
- Completed
- Registry status
- 83
- Enrollment target
- 20
- Study locations
NCT01375127: Completed study of Kidney Transplantation, sponsored by Pfizer.
NCT01375127 is a study of Kidney Transplantation that has completed, run by Pfizer. The registered enrollment target is 83 participants, below the 265-participant average among 33 other Kidney Transplantation trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01375127, a study of Kidney Transplantation, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 83 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an observational study designed to collect follow-up clinical date on subjects who were treated with tofacitinib in 2 completed Phase 2 studies who either discontinued treatment prematurely or did not elect to enroll in long-term extension studies.
Primary Outcome
All lymphoproliferative disorders diagnosed locally as PTLD based on histopathology were reported.
Conditions Studied
Interventions
- DRUG Tofacitinib
Study Locations (20)
California
- Pfizer Investigational Site - Los Angeles
- Pfizer Investigational Site - Los Angeles
- Pfizer Investigational Site - Palo Alto
- Pfizer Investigational Site - San Francisco
- Pfizer Investigational Site - San Francisco
- Pfizer Investigational Site - Stanford
Illinois
- Pfizer Investigational Site - Chicago
- Pfizer Investigational Site - Chicago
Massachusetts
- Pfizer Investigational Site - Boston
- Pfizer Investigational Site - Springfiled
Michigan
- Pfizer Investigational Site - Ann Arbor
- Pfizer Investigational Site - Detroit
New York
- Pfizer Investigational Site - New York
- Pfizer Investigational Site - Valhalla
Colorado
- Pfizer Investigational Site - Aurora
Florida
- Pfizer Investigational Site - Tampa
Missouri
- Pfizer Investigational Site - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2011-08 |
| Est. Completion | 2012-07 |
What the finished NCT01375127 record still lists
NCT01375127 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 83 participants, a relatively small participant target, below the 265-participant average among 33 other Kidney Transplantation trials with a reported enrollment target (69% lower).
The record links to 1 condition, with Kidney Transplantation appearing as the primary indexed condition, and to 1 intervention - of which Tofacitinib is the first listed.
NCT01375127 names 20 study sites across 11 states, led by California, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01375127 about?
NCT01375127 is a clinical study titled "Collection of Follow-up Data From CP-690,550-treated Kidney Transplant Recipients". This is an observational study designed to collect follow-up clinical date on subjects who were treated with tofacitinib in 2 completed Phase 2 studies who either discontinued treatment prematurely or did not elect to enroll in long-term extension studies.
What is the current status of trial NCT01375127?
This trial is currently completed. The enrollment target is 83 participants. The study started on 2011-08. Estimated completion is 2012-07.
What conditions does trial NCT01375127 study?
This clinical trial studies the following conditions: Kidney Transplantation.
What interventions are being tested in trial NCT01375127?
The interventions under investigation include: Tofacitinib (DRUG).
Who is sponsoring clinical trial NCT01375127?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01375127 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Transplantation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01375127's enrollment target sits among peer trials
83 18th of 33 higher than 16 of 33 other Kidney Transplantation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Transplantation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reduced Immunosuppression in Older Renal Transplant Recipients With Trugraf®/TRAC Monitoring (RIOT Trial): A Prospective, Randomized, Multicenter Trial.
RECRUITING · Phase 4
-
Shared Decision Making for Kidney Transplant Candidates to Plan for an Organ Offer Decision
RECRUITING · NA
-
Prehabilitation for Kidney Transplant Candidates
RECRUITING · NA
-
REgulatory T Cell Therapy to Achieve Immunosuppression REduction
RECRUITING · Phase 2
-
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
RECRUITING · Phase 2
-
Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02974647 · 83 participants · Phase 2
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
- NCT03919292 · 83 participants · Phase 1
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
- NCT04626674 · 83 participants · Phase 1
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
- NCT05277168 · 83 participants · Phase 1
A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia